A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE [apolipoprotein E] e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1).

Trial Profile

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE [apolipoprotein E] e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Rosiglitazone (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms REFLECT-1
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2009 Actual initiation date changed from Jan 2007 to Feb 2007 as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top